Collectively, our data revealed that NAD+ improved cognitive function and reduced neuroinflammation in CCH models in vivo and vitro, and these treatment effects were associated with mitochondrial protection and ROS inhibition through the activation of Sirt1/PGC-1α pathway. This evidence concerns the gene PPARGC1A and columnar cell hyperplasia of the breast.